Vaccines and therapeutics for immunocompromised patients with COVID-19

S Shoham, C Batista, YB Amor, O Ergonul… - …, 2023 - thelancet.com
The COVID-19 pandemic has disproportionately impacted immunocompromised patients.
This diverse group is at increased risk for impaired vaccine responses, progression to …

An overview on nanoparticle-based strategies to fight viral infections with a focus on COVID-19

S Yasamineh, HG Kalajahi, P Yasamineh… - Journal of …, 2022 - Springer
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) led to COVID-19 and has
become a pandemic worldwide with mortality of millions. Nanotechnology can be used to …

[HTML][HTML] Real-world experience with available, outpatient COVID-19 therapies in solid organ transplant recipients during the omicron surge

C Radcliffe, CF Palacios, MM Azar, E Cohen… - American Journal of …, 2022 - Elsevier
The SARS-CoV-2 pandemic continues to place a substantial burden on healthcare systems.
Outpatient therapies for mild-to-moderate disease have reduced hospitalizations and deaths …

Analysis of postvaccination breakthrough COVID-19 infections among adults with HIV in the United States

SB Coburn, E Humes, R Lang, C Stewart… - JAMA network …, 2022 - jamanetwork.com
Importance Recommendations for additional doses of COVID-19 vaccines for people with
HIV (PWH) are restricted to those with advanced disease or unsuppressed HIV viral load …

The immune response to SARS-CoV-2 in people with HIV

MA Höft, WA Burgers, C Riou - Cellular & Molecular Immunology, 2024 - nature.com
This review examines the intersection of the HIV and SARS-CoV-2 pandemics. People with
HIV (PWH) are a heterogeneous group that differ in their degree of immune suppression …

COVID-19 vaccination for the prevention and treatment of long COVID: A systematic review and meta-analysis

F Ceban, D Kulzhabayeva, NB Rodrigues… - Brain, behavior, and …, 2023 - Elsevier
Empirical evidence addressing the association between SARS-CoV-2 vaccination and long
COVID would guide public health priorities and inform personal health decisions. Herein …

[HTML][HTML] Breakthrough SARS-CoV-2 infections with the delta (B. 1.617. 2) variant in vaccinated patients with immune-mediated inflammatory diseases using …

L Boekel, EW Stalman, L Wieske… - The Lancet …, 2022 - thelancet.com
Background Concerns have been raised regarding the risks of SARS-CoV-2 breakthrough
infections in vaccinated patients with immune-mediated inflammatory diseases treated with …

Association between AZD7442 (Tixagevimab-Cilgavimab) administration and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection …

J Kertes, S Shapiro Ben David… - Clinical Infectious …, 2023 - academic.oup.com
Background Intramuscular AZD7442 (tixagevimab–cilgavimab [Evusheld; AstraZeneca]) has
been found effective among immunocompromised individuals (ICIs) in reducing SARS-CoV …

Remdesivir reduced mortality in immunocompromised patients hospitalized for COVID-19 across variant waves: findings from routine clinical practice

E Mozaffari, A Chandak, RL Gottlieb… - Clinical Infectious …, 2023 - academic.oup.com
Background Immunocompromised patients are at high risk of severe coronavirus disease
2019 (COVID-19) and death, yet treatment strategies for immunocompromised patients …

Analysis of severe illness after postvaccination COVID-19 breakthrough among adults with and without HIV in the US

R Lang, E Humes, SB Coburn, MA Horberg… - JAMA network …, 2022 - jamanetwork.com
Importance Understanding the severity of postvaccination SARS-CoV-2 (ie, COVID-19)
breakthrough illness among people with HIV (PWH) can inform vaccine guidelines and risk …